| | |
| Clinical data | |
|---|---|
| Other names | GYKI32887; RGH-7825; RGH7825; 8-((N-2-Azidoethyl-N-methylsulfonylamino)methyl)-6-methylergol-8-ene |
| Drug class | Dopamine agonist; Antiparkinsonian agent |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C19H24N6O2S |
| Molar mass | 400.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
GYKI-32887, also known as RGH-7825, is a dopamine agonist and antiparkinsonian agent of the ergoline family which was never marketed. [1] [2] [3] [4] It has a lysergamide-like structure but is not technically a lysergamide itself. [1] Similarly to other D2-like receptor agonists, direct injection of small doses of GYK-32887 into the nucleus accumbens decreases locomotor activity in rodents. [3] This effect can be blocked by D2-like receptor antagonists like haloperidol, fluphenazine, and sulpiride. [3] GYKI-32887 was first described in the scientific literature by 1983. [2] [3] [4]